Evidence map›Paper›PMID 31321417›Full record

ArticleRheumatology (Oxford, England)2020

Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus.

Daniel Li, Kazuki Yoshida, Candace H Feldman, Cameron Speyer, Medha Barbhaiya, Hongshu Guan, Daniel H Solomon, Brendan M Everett, Karen H Costenbader

Erratum issuedAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Vascular damage in systemic lupus erythematosus.Nature reviews. Nephrology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Daniel LiDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Kazuki YoshidaDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Candace H FeldmanDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Cameron SpeyerDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Medha BarbhaiyaDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Hongshu GuanDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Daniel H SolomonDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.
Brendan M EverettDivisions of Cardiovascular and Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Karen H CostenbaderDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, MA, USA.

Funding

Sociodemographic Disparities in SLE Incidence: Behavioral and Psychosocial FactorsR01AR057327 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2009 to 2019
$6.2M
Cardiovascular Disease Epidemiology in Patients with LupusK24AR066109 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2014 to 2023
$1.7M
NIAMS NIH HHS K24 AR066109NIAMS NIH HHS R01 AR057327
6 · The paper itself

Abstract

objectiveSLE is associated with high risks of cardiovascular disease (CVD) and mortality, and has a wide spectrum of presentations. We investigated whether SLE severity at diagnosis was associated with CVD or mortality risk.

methodsWithin Medicaid (2000-10), we identified patients 18-65 years of age with incident SLE. Initial SLE severity was classified-mild, moderate, or severe-during the baseline year prior to the start of follow-up (incident index date) using a published algorithm based on SLE-related medications and diagnoses. Patients were followed from the index date to the first CVD event or death, disenrollment, loss to follow-up or end of follow-up period. Cox and Fine-Gray regression models, adjusted for demographics and comorbidities accounting for the competing risk of death (for CVD), estimated CVD and mortality risks by baseline SLE severity.

resultsOf 15 120 incident SLE patients, 48.7% had mild initial SLE severity, 33.9% moderate and 17.4% severe. Mean (s.d.) follow-up was 3.3 (2.4) years. After multivariable adjustment, CVD subdistribution hazard ratios (HRSD) were higher for initially severe [HRSD 1.64 (95% CI 1.32, 2.04)] and moderate [HRSD 1.19 (95% CI 1.00, 1.41)] SLE vs mild SLE. Mortality HRs were also higher for initially severe [HR 3.11 (95% CI 2.49, 3.89)] and moderate [HR 1.61 (95% CI 1.29, 2.01)] SLE vs mild SLE.

conclusionSLE patients with high initial severity had elevated mortality and CVD events risks compared with those who presented with milder disease. This has implications for clinical care and risk stratification of newly diagnosed SLE patients.

Indexed as

AdolescentAdultAgedCardiovascular DiseasesFemaleHumansIncidenceLupus Erythematosus, SystemicMaleMiddle AgedRiskSeverity of Illness IndexSurvival RateYoung Adultcardiovascular diseaseseveritysystemic lupus erythematosus

Identifiers

PMID31321417
PMCPMC7759736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.